ARPC1B and neoplasm: This approach, however, presents dual therapeutic challenges: ARPC1B deficiency compromises cytotoxic T lymphocyte effector functions as demonstrated by impaired tumor cell killing and attenuated IFN-γ secretion in standardized systems [25], while close structural homology with ARPC1A raises toxicity and specificity concerns [45].